● pepmg Research Desk · Peer-reviewed evidence review
What the research says about GHRP-6
A neutral summary of the peer-reviewed literature on GHRP-6, a synthetic growth-hormone-releasing hexapeptide studied in short human growth-hormone-stimulation and diagnostic trials. Research use only.
Moderate evidence — Limited human trials — often early-phase. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- GHRP-6 is a synthetic growth-hormone-releasing hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates the pituitary to release growth hormone through a receptor distinct from the GH-releasing hormone receptor, and it was the first such peptide studied extensively in humans [1][2].
- Human randomized and clinical trials have measured its growth-hormone-releasing effect, including a synergistic response when GHRP-6 is combined with GH-releasing hormone (GHRH) [3][2].
- These are short growth-hormone-stimulation and diagnostic studies (for example, testing pituitary growth-hormone reserve), not long therapeutic outcome trials [5][6].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What GHRP-6 is
GHRP-6 is described in the literature as a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that stimulates growth-hormone secretion in a specific, dose-related manner and acts through mechanisms and receptors distinct from those of growth-hormone-releasing hormone (GHRH) [1][2]. Reviews describe it as the first growth-hormone-releasing peptide to be studied extensively in humans, with a probable dual site of action at both the pituitary and the hypothalamus [1].
Mechanistic work in cultured human pituitary tumour cells reported that GHRP-6 stimulates membrane phosphatidylinositol turnover in parallel with growth-hormone release, consistent with signalling through protein kinase C and intracellular calcium rather than cyclic AMP [8]. Material sold by third-party research-chemical vendors is not an approved medicine and is offered for laboratory and research use only.
What the human research has measured
Moderate evidenceThe human GHRP-6 studies have mostly measured growth-hormone responses to acute challenge. A randomized study in healthy young and older adults reported that growth-hormone responses to GHRP-6 were much greater than to GHRH in late adulthood, and that combining GHRH with GHRP-6 produced a greater response than either agent alone, which the authors read as evidence that age-related decline in growth-hormone secretion is functional and potentially reversible [3]. A randomized study using acute oral dexamethasone before the peptides reported that dexamethasone enhanced growth-hormone responsiveness to GHRP-6, suggesting the two act at different points in the growth-hormone-releasing pathway [4].
GHRP-6 has been examined as a diagnostic probe of pituitary function. A clinical trial in patients with growth-hormone deficiency from perinatal pituitary stalk transection reported that GHRH plus GHRP-6, though the most potent stimulus tested, failed to raise growth hormone above a low threshold in those patients, supporting its use in identifying that condition [5]. A review evaluating GHRP-6 as a test of pituitary growth-hormone reserve reported considerable overlap between deficient and normal children on an individual basis, but a near-complete absence of response in pituitary stalk transection [6]. A comparison against the insulin tolerance test reported that GHRP-6, alone or with GHRH, identified adults with growth-hormone deficiency, and that the observed side effects during administration were flush symptoms [7]. A further study reported that growth-hormone responses to GHRH plus GHRP-6 were significantly reduced in severely obese men, limiting a single diagnostic cut-off in that group [6].
What the trials report on safety and adverse events
Moderate evidenceThe GHRP-6 human studies are short growth-hormone-stimulation and diagnostic protocols, so their safety information reflects brief exposure. In a study comparing GHRP-6 testing against the insulin tolerance test, the authors reported that the only side effects observed during GHRP-6 administration were flush symptoms [7].
These are small, short-duration endocrine and diagnostic studies, not large or long safety trials, and much of the human work used GHRP-6 as an acute research or diagnostic probe of growth-hormone regulation [3][5][6]. This is not medical advice; the human safety of GHRP-6 outside these research settings is not established. Consult a qualified professional and read the studies directly.
How strong is the evidence
Because GHRP-6's growth-hormone-releasing effect has been measured in human randomized controlled trials and a clinical trial [3][4][5], the evidence base is characterized as moderate relative to the preclinical-only peptides in this library. "Moderate" describes the design and species of the published trials, and it is important to note their scope: these are short growth-hormone-stimulation and diagnostic studies of pituitary function, not long therapeutic outcome trials. GHRP-6 is a distinct hexapeptide from the related secretagogue GHRP-2, though the two are often studied side by side [2].
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 8
- Growth hormone-releasing peptides and their analogs.
- Growth hormone-releasing peptides.
- Growth hormone secretion after the administration of GHRP-6 or GHRH combined in young and old subjects.
- Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6.
- Absence of growth hormone (GH) secretion after the administration of GHRP-6 in patients with perinatal pituitary stalk transection.
- The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men.
- Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH.
- Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol turnover in human pituitary somatotrophinoma cells.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.